Ignite Creation Date:
2024-05-05 @ 11:13 PM
Last Modification Date:
2024-10-26 @ 10:30 AM
Study NCT ID:
NCT01286753
Status:
COMPLETED
Last Update Posted:
2016-09-07
First Post:
2011-01-28
Brief Title:
A Study of Vemurafenib RO5185426 in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
An Open-Label Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients With Metastatic or Unresectable Papillary Thyroid Cancer PTC Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine
Status:
COMPLETED
Status Verified Date:
2016-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This open-label multi-center study will evaluate the safety and efficacy of Vemurafenib RO5185426 in participants with metastatic or unresectable papillary thyroid cancer PTC positive for the BRAF V600 mutation and resistant to radioactive iodine therapy Participants will receive vemurafenib 960 milligrams mg orally twice daily until progressive disease or unacceptable toxicity occurs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2010-024133-23 | None | None | None |